Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | HPGDS | O60760 | 10/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL622031 | 0.92 | HPGDS (0.32) | CHRNB2CHRNA7CHRNA4HPGDSMAOB | |
| SCHEMBL620702 | 0.86 | HPGDS (0.35) | HPGDS | |
| SCHEMBL622276 | 0.74 | FGFR1 (0.32) | — | |
| SCHEMBL621790 | 0.72 | — | — | |
| SCHEMBL620720 | 0.70 | ALDH1A1 (0.46) | CHRNB2CHRNA7CHRNA4HPGDSALDH1A1 | |
| SCHEMBL620719 | 0.70 | ALDH1A1 (0.46) | CHRNB2CHRNA7CHRNA4HPGDSALDH1A1 | |
| SCHEMBL621678 | 0.67 | MAOB (0.40) | CHRNB2CHRNA7CHRNA4HPGDSALDH1A1 | |
| SCHEMBL621677 | 0.67 | MAOB (0.40) | CHRNB2CHRNA7CHRNA4HPGDSALDH1A1 | |
| SCHEMBL5653235 | 0.65 | KCNH2 (0.35) | — | |
| SCHEMBL622029 | 0.65 | ALDH1A1 (0.41) | HPGDSALDH1A1KDM4EHSD17B10MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133219-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-09-15 | — | — | US | claimed |
| US-20150080373-A1 | NOVEL BICYCLIC ANTIBIOTICS | Basiliea Pharmaceutica AG | 2015-03-19 | — | — | US | claimed |
| US-9133219-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-09-15 | — | — | US | disclosed |
| US-20150080373-A1 | NOVEL BICYCLIC ANTIBIOTICS | Basiliea Pharmaceutica AG | 2015-03-19 | — | — | US | disclosed |
| US-8927542-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-01-06 | — | — | US | disclosed |
| US-20140221348-A1 | NOVEL BICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2014-08-07 | — | — | US | disclosed |
| US-8716280-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2014-05-06 | — | — | US | disclosed |
| US-20120040957-A1 | Novel Bicyclic Antibiotics | BASILEA PHARMACEUTICA AG | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040957-A1 | Novel Bicyclic Antibiotics | C5, C1S, CBR3 | CHRNB2 2501/4885CHRNA7 3372/4885CHRNA4 1834/4885 |
| US-20140221348-A1 | NOVEL BICYCLIC ANTIBIOTICS | C1S, XPA, XDH | CHRNB2 3148/4885CHRNA7 3773/4885CHRNA4 2192/4885 |
| US-20150080373-A1 | NOVEL BICYCLIC ANTIBIOTICS | C1S, XPA, XDH | CHRNB2 3148/4885CHRNA7 3773/4885CHRNA4 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.